HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.04601007v1 3/4/1077    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Kilpatrick, R. D. Articles by Bradbury, B. D. PubMed PubMed Citation Articles by Kilpatrick, R. D. Articles by Bradbury, B. D. Related Collections Related Articles

Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients

Ryan D. Kilpatrick^*, Cathy W. Critchlow^*, Steven Fishbane, Anatole Besarab, Catherine Stehman-Breen, Mahesh Krishnan^||, and Brian D. Bradbury^*

Departments of ^* Biostatistics & Epidemiology, Clinical Development, and ^|| Medical Affairs, Amgen Inc, Thousand Oaks, California; Division of Nephrology & Hypertension, Department of Medicine, SUNY at Stony Brook, Stony Brook, New York; and Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan

Correspondence: Dr. Ryan D. Kilpatrick, Department of Biostatistics & Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24-2-A, Thousand Oaks, CA 91320. Phone: 805-313-4271; Fax: 805-447-1984; E-mail: rkilpatr{at}amgen.com

Background and objectives: Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated.

Design, setting, participants, & measurements: Data from 321 participants were used and randomized to the hematocrit normalization arm of the Normal Hematocrit Cardiac Trial. Subjects were to receive a 50% Epoetin alfa dose increase at randomization. The prospective erythropoietin responsiveness measure was defined as the ratio of weekly hematocrit change (over the 3 wk after randomization) per Epoetin alfa dose increase (1000 IU/wk) corresponding to the mandated 50% dose increase at randomization. The distribution of responsiveness was divided into quartiles. Over a 1-yr follow-up, Cox proportional hazard modeling evaluated associations between this responsiveness measure and mortality.

Results: Erythropoietin responsiveness values ranged from –2.1% to 2.4% per week per 1000 IU. Although subjects were similar across response quartiles, mortality ranged between 14% and 34% among subjects in the highest and lowest response quartiles (P = 0.0004), respectively. After adjusting for baseline prognostic indicators, highest versus lowest responsiveness was associated with a hazard ratio of 0.41 (95% confidence interval, 0.20 to 0.87).

Conclusion: Lower erythropoietin responsiveness is a strong, independent predictor of mortality risk and should be considered when evaluating associations between clinical outcomes and potential prognostic indicators, such as Epoetin alfa dose and achieved hemoglobin values.

Related Articles

Erythropoietin Stimulating Agents and Epoetin Alfa Revisited: What's Really Relevant?

Rowan G. Walker
Clin. J. Am. Soc. Nephrol. 2008 3: 935-937. [Full Text] [PDF]

This article has been cited by other articles:

				R. G. Walker Erythropoietin Stimulating Agents and Epoetin Alfa Revisited: What's Really Relevant? Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 935 - 937. [Full Text] [PDF]